Recent Articles

Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L, Perlin DS.
Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis.
Antimicrob Agents Chemother 2002 Aug;46(8):2704-7
PMID: 12121962

Cochleates containing amphotericin B (CAMB) were administered orally at doses ranging from 0 to 40 mg/kg of body weight/day for 14 days in a murine model of systemic aspergillosis. The administration of oral doses of CAMB (20 and 40 mg/kg/day) resulted in a survival rate of 70% and a reduction in colony counts of more than 2 logs in lungs, livers, and kidneys. Orally administered CAMB shows promise for the treatment of aspergillosis.